Nuvectis Pharma, Inc. (NVCT)
Nasdaq: NVCT · Pharmaceutical Preparations · Fort Lee, NJ · filing with the SEC since 2021
Who runs Nuvectis Pharma, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Bentsur Ron
Chairman & CEO. First filing Feb 2022, latest Jul 1, 2026, 47 filings in all.
Officers reporting now
4
of 8 people with a filing in the last fifteen months
Directors reporting now
4
9 people on the record since 2022
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Carson Michael J. | Vice President, Finance | Mar 2022 | Aug 5, 2026 | none |
| Bentsur Ron | Chairman & CEO | Feb 2022 | Jul 1, 2026 | none |
| Poradosu Enrique | Chief Science & Business Off | Feb 2022 | Jan 9, 2026 | none |
| Shemesh Shay | Chief Dev. & Ops. Officer | Feb 2022 | Jan 9, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Hoberman Kenneth | director | Feb 2022 | Jun 12, 2026 | none |
| Kaplan Matthew L. | director | Feb 2022 | Jun 12, 2026 | none |
| Oliviero James F III | director | Feb 2022 | Jun 12, 2026 | none |
| Sanchez Juan | director | Sep 2025 | Jun 12, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Mosseri Marlio Charles | 10% owner | Jun 2023 | Jul 1, 2026 | none |
Earlier names on the record1, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.